INTRODUCTION
Datamonitor estimates that there are 307m people in the seven major markets
with total cholesterol >200mg/dL and this is set to rise to 328m in 2011.
However, low diagnosis rates, the launch of generic statins and the maturing of
the market make it increasingly important for companies to target the
under-treated dyslipidemia sub-populations.
SCOPE OF THE REPPORT
- Dyslipidemia patient potential, including current and forecast future
prevalence of high total cholesterol
- Use of anti-dyslipidemics in dyslipidemia sub-populations and treatment
variation between each population
- Insight on trends in the use of combination therapy and potential role and
uptake of adjunctive therapies
- Physician awareness, perception and expected future prescribing rates for
new agents, such as Zetia (ezetimibe) and Crestor (rosuvastatin)
REPORT HIGHLIGHTS
Statins remain the first line therapy for diabetic dyslipidemia, following
recommendations from the American Diabetes Association, and findings from HPS
and CARDS. However, some experts believe that results from DAIS and VA-HIT
support the use of fibrates as the lipid-lowering agents of choice in diabetic
dyslipidemics.
Although the use of combination therapy varies considerably
across the seven major markets, this treatment strategy is becoming increasingly
more common as treatment guidelines recommend more aggressive therapy in order
to achieve lower target cholesterol goals and physicians remain reluctant to
titrate statin doses.
New anti-dyslipidemics must demonstrate the potential to
improve outcomes by improving efficacy, safety or both. Opinion leaders
interviewed for this Analysis remain considerably more optimistic over the
future uptake of Zetia than Crestor.
KEY REASONS TO BUY THIS REPORT
- Understand how physicians are influenced in their prescribing practices
when treating dyslipidemia
- Identify and quantify the 'difficult-to-treat' dyslipidemic populations
- Recognize lucrative target populations, in terms of unmet need and patient
potential
View Cart
